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Therapeutic development for neurological diseases, whether
cerebrovascular disease, vascular dementia, or Alzheimer’s
disease (AD), has been largely unsuccessful. Despite the ap-
parent success of numerous pharmacologic agents in pre-
clinical animal models, few have translated successfully from
benchtobedside.Assuch,avastneedremainsunmetandad-
ditional investigation is required.
Speculation concerning the reasons for this failed trans-
lation from bench-to-bedside often highlights either the lack
of reproducibility or a poor choice of the outcome measure
parameters. However, in most of the literature, the lack of
clinical relevance of the animal model used often goes unno-
ticed. The role of age in neurologic disease development is
well known, in fact, age is the greatest risk factor for develop-
ment of AD as well as stroke. In sharp contrast to this clinical
reality, the vast majority of preclinical studies utilize young
or young-adult animal models of neurologic disease, despite
the suggestion of collaborative advisory groups such as the
StrokeTherapyAcademicandIndustryRoundtable(STAIR).
The ageing process aﬀects various biological axes, from
the status of the cardiovascular system to the status of the
inﬂammatoryresponsivenessandﬁnallytothechangesinthe
ability of the neural systems to handle pathological insults
and a signiﬁcant reduction in the recovery capability. At one
end of this spectrum of changes in cerebral cardiovascular
status are the morphological changes in vasculature, mani-
fested as large increases in the vascular path due to increased
tortuosity of arterioles in the deep white matter [1]a n d
an age-associated decrease in capillary number and length,
leading to a signiﬁcant increase (25%) of the intercapillary
distance in both the hippocampus and cortex [2] and white
matter [3]. Such processes would lead to tissular hypoxia
that in young or adult brain would trigger an angiogenesis
response, mediated by HIF-1 as a transcription factor for
VEGF. However, in the aged brain, there is a reduction in
the angiogenesis response, due to decreased responsiveness
to HIF-1. Such age-associated changes in the blood vessels
architecture are even more relevant to the brain, because of
the speciﬁcs of vascularization: the system of feeding arteries
is situated near the surface of the brain, from where end-
arteries are penetrating through the gray and white matter
in a network that terminates in a capillary bed but with very
few shunts [4].
As a result of such anatomical changes, there is little sur-
prise that in the aged brain there is a signiﬁcant reduction in
the cerebral blood ﬂow (CBF), aﬀecting mainly the cortex,
and more sparingly the subcortical regions, as revealed by
a variety of imaging techniques, from positron-emission
tomography (PET) and single-photon emission computed
tomography (SPECT) to high-resolution, contrast-enhanced
MRI and arterial-spin labeling (ASL) [5]. However, as it
has been pointed out [6], CBF is aﬀected not only by mor-
phological changes, but it is also modulated by a variety of
functional parameters such as perivascular innervation [7],2 Journal of Aging Research
astroglialcontrolofarteriolarconstriction[8],andautocrine
endothelial signaling in response to rheostatic forces and
neural environment [9].
For the clinical category of cerebrovascular diseases, the
stroke is, by a distance, the most signiﬁcant entity, both in
terms of prevalence and consequences. The stroke can result
from either an occlusion of the vessel (ischemia), which
can be either transient (e.g., the transient ischemic attack,
TIA) or of longer duration; or from the rupture of a vessel,
leading to regional hemorrhage, either within the cortical
matter or in the dural cavities. While the biological and
medical consequences of a stroke are signiﬁcant at any age,
the incidence and the severity of a stroke are signiﬁcantly
increased with age. The paper from Russo et al. provides a
systematic review, looking at the ﬁrst stroke incident and
shows that the trend continues for the very old (older than
80 years old).
Several factors are likely contributors to this increased
severity of stroke with age. One such factor is a metabolic
decrease in the capacity of neural cells to counteract extreme
stressors and/or neurotoxic challenges (decreased metabolic
reserve) [10] that appear in the penumbra region of a stroke,
in which a combination of hypoxia and resulting decrease in
ATPprovisionswillleadtothegenerationofahyperexcitable
environment, posing signiﬁcant metabolic challenges.
Stroke in the very old is a very frequent condition, with
anunfavourableoutcome,andmakesarelevantcontribution
to the social burden of stroke and may require more eﬃcient,
dedicated stroke services (Russo et al.). Aged individuals
recover less well from stroke, and rehabilitation aims at
improving the physical and cognitive impairments and dis-
abilities of patients with stroke. Therefore, studies on behav-
ioral recuperation after stroke in aged animals are necessary.
Various experimental settings have been used to assess the
recovery of sensorimotor functions, spontaneous activity,
and memory after ischemia in aged rats. Overall, the results
indicate that aged rats have the capacity to recover behav-
iorallyaftercorticalinfarcts,albeittoalesserextentthantheir
young counterparts [11, 12]. It should be kept in mind, how-
ever,thatbeforestrokeagedratsarealreadyimpairedascom-
paredtoyounganimalsandshowsigniﬁcantlydecreasedper-
formance in some tests like spontaneous activity [13]. Accel-
erated glial reactivity to stroke in aged rats correlates with
reduced functional recovery [13] including Morris water-
maze [14]. Behavioral and histological eﬀects of chronic
antipsychotic and antidepressant drug treatment in aged rats
with focal ischemic brain injury are discussed in [14].
Another crucial component of the brain tissue response
to stroke is the inﬂammatory response. As reviewed in the
article by Shah and Di Napoli (2011) the age-associated
changes in the immune function determine that in the
aged and individuals, the response to an acute stroke
involves a more intense inﬂammatory reaction in the ﬁrst
phase of acute ischemia, involving cytokine activation and
chemokine expression that lead to an early scar formation
and ﬁbrosis. In agreement with previous observations [15],
the article also points out the fact that the biology of the
aged brain is diﬀerent from that of the young brain, and
this has signiﬁcant implications for the current translational
eﬀorts to deﬁne eﬀective therapies, since a large majority of
interventional studies are performed on young and young-
adult animals.
Anotherimportantperspectiveinassertingnewpotential
therapeutical interventions for stroke is to assess if the diﬀer-
ences in responsiveness between young adult and old brains
are due only to functional changes or if they involve more
elaborate changes in protein expression. Recent detailed
analyses of the genomics data from adult and aged animals
indicate changes in the balance of the various systems and
regulatory processes. Using categorized DNA arrays, we
found inappropriate gene regulation in response to stroke
both in the ipsilateral and the contralateral hemisphere
of aged rats. The gene expression proﬁle in the brains of
poststroke aged rats is indicative of increased cell death due
to DNA damage and apoptosis, especially in the ﬁrst week
afterstroke.Similarly,wereportedpersistentdownregulation
of genes that are required for neurogenesis after stroke in
aged rats [16].
However, the category of cerebrovascular diseases is not
restricted to the pathologies involving the large vessels. Cere-
bral small vessels disease (cSVD) is a group of pathological
processes associated with established vascular risk factor
such as hypertension, atherosclerosis, diabetes mellitus, and
atrial ﬁbrillation. The consequences of small vessel disease
on the brain parenchyma are mainly lesions located in
the subcortical structures such as lacunar infarcts, white
matter lesions, large hemorrhages, and microbleeds. This
compendium of tissue lesions has been compiled in the last
decade or so by the ever expanding use of more powerful and
sensitive brain imaging technologies, rather than by a better
understanding or direct assessment of actual small vessels
territories. As a result, the cerebral small vessels diseases are
now invoked in explaining a variety of clinical syndromes,
and van Uden and collaborators discuss in their paper the
possibility that such vascular pathology is underlining the
clinical manifestations of the late onset depression in the
agedpeople(I.W.vanUdenetal.(2011)).Evenmoredaring,
Teggietal.proposethatcSVDmightalsoexplainsomeforms
of the Meniere disease [17].
Another area of neuropathology in which small vessel
diseasehasawell-establishedrolethatgatherseverincreasing
recognition in both the clinical and basic research world is
that of being a leading cause of cognitive decline and func-
tional loss in the elderly. Vascular dementia is a broad con-
cept that has evolved slowly. While general anecdotal refer-
ences linking putative cerebral vascular events with reduc-
tions in cognitive performance have existed for long time, it
is the articles of Binswanger and Alzheimer around the turn
of the 20th century describing in detail the various types of
vascular lesions that could be encountered in human brains
that set the ﬁeld on a strong morphopathological footing,
and it took another 70 years until Hachinski suggested that
dementia of vascular origin was a consequence of multiple
strokes [18]. Subsequently, the concept continued to evolve
to include multiple mechanisms related to deﬁciencies in
cerebral blood supply, including large vessel disease, small
vessel pathology, consequences of cerebral hypoperfusion
and hemorrhage.Journal of Aging Research 3
While the risk factors for vascular diseases are relatively
well established, much less consensus exists on the speciﬁc
risk factors for vascular dementia, that is, apart, from the
acknowledged role of increased age. Ongoing interest in
cerebrovascular diseases research has provided data showing
that Alzheimer’s proteins and other factors may be involved
in the pathogenesis of gradual ischemic brain injury. Thus,
both focal and global brain ischemia in rodents produce
a stereotyped pattern of selective neuronal degeneration,
which is just the same as in Alzheimer’s type dementia. As
hypothesized in the article by Enciu et al., there is an overlap
of events between chronic hypoxia and AD on several levels,
such as hypoxic-triggered cellular pathways, inﬂammatory
environment, growth factor signaling, and calcium home-
ostasis. A reduction of CBF and a series of molecular events
precede the major ischemic events in vascular cognitive
impairment. Based on these subtle changes, intervention at
early stages could prevent the full-blown development of
dementia, which might represent a “point of no return” for
the neurovascular units and neuronal networks with few
chances for eﬃcient treatment. In their extensive review,
Enciu and her colleagues also discuss some of the molecular
mechanisms that are triggered by the cerebrovascular
diseases and that lead to overcognitive dysfunction and
argue convincingly the case for an early intervention at the
point at which the dysfunction of the neurovascular units is
still potentially reversible.
However, it is important to keep in mind that the genetic
makeup is a hugely important factor, from the subtle alter-
ations inthefunctionofvarious proteins (e.g.,ApoE4) tothe
overt cerebrovascular diseases with a genetic control, as the
cerebralautosomalarteriopathywithsubcorticalinfarctsand
leukoencephalopathy (CADASIL) that involves mutations in
Notch-3 protein. Equally important is the discovery that
fundamental genetic changes may occur with aging, such
as the CLOCK genes, as discussed by Thome et al. (2011).
Taken together, aging may result in fundamental changes
throughout the body, beginning at a gene level and progress-
ing to protein expression or posttranslational modiﬁcation
level.
It is clear that the quest for improved therapeutics will
require increased understanding of disease pathophysiology
and, in particular, the changes induced by the aging process.
Similarly, neurologic disease research has often maintained
a “neurocentric” focus, in which the role of the neuron
was emphasized. This is unlikely to result in successful
development of therapeutics due to the intimate relationship
evident between neurons, surrounding glia, and the neu-
rovascular unit—in both health and disease. The eﬀect of
agingonastrocyteandmicroglialresponsetoinjuryandhow
this process can be manipulated successfully for therapeutic
development must be considered.
Similarly, preclinical studies of neurologic disease uti-
lizing aged animals must incorporate functional outcome
measures in addition to histological measures. Clinically, the
primary assessment remains functional outcome and pres-
ence/absence of signiﬁcant disability yet preclinical studies
often emphasize histological outcomes such as infarct vol-
ume. The diﬃculty of identifying high ﬁdelity functional
studies in aged animals remains a vexing problem.
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